Add Yahoo as a preferred source to see more of our stories on Google. Global health foundation Coalition for Epidemic Preparedness Innovations (CEPI) will invest $50 million to support development and ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Coalition for Epidemic ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news like ...

Moderna (MRNA) is in the early stages of developing a hantavirus vaccine, though its availability could be years away. Shares are up ~14% in Friday afternoon trading. Hantavirus has received renewed ...

Moderna Inc. said it’s researching vaccines to protect against hantaviruses, even as public health experts downplay the risk the deadly pathogen aboard a cruise ship could become a significant threat.

Moderna's MRNA.O mRNA-based seasonal flu vaccine worked better than conventional flu shots in a late-stage international trial of more than 40,000 adults aged 50 and older, researchers reported on ...

The efficacy of flu shots is not always the same and it’s not always optimal. Some years, they can reduce the risk of illness by as little as 20% to 30%. Subscribe to read this story ad-free Get ...

Moderna’s mRNA-based combination vaccine against both flu and COVID-19 has gotten the green light in Europe—but it continues to be shelved in the US, where it was developed. This week, the European ...

Companies are playing word games with promising cancer treatments. Is it the Department of Defense or the Department of War? The Gulf of Mexico or the Gulf of America? A vaccine—or an “individualized ...

As mentioned, Moderna experienced significant growth in the early stages of the coronavirus crisis as it quickly commercialized and delivered a vaccine. This was the company's first and only product ...

Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...

Moderna said it settled patent lawsuits over its blockbuster COVID-19 vaccine for $950 million, with another $1.3 billion payout possible depending on the outcome of a federal appeal. The ...